×
About 215 results

ALLMedicine™ Pediatric Neuroblastoma Center

Research & Reviews  105 results

Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed t...
https://doi.org/10.1007/s00247-021-05005-y 10.1016/S0140-6736(07)60983-0 10.1001/jama.2019.11642 10.1200/JCO.2008.16.6876 10.18632/oncotarget.7933 10.1200/JCO.2001.19.14.3397 10.2967/jnumed.108.060467 10.1016/j.ejrad.2015.09.027 10.1007/s13139-016-0451-8 10.2967/jnumed.110.083303 10.1097/RLU.0000000000001529
Pediatric Radiology; Sung AJ, Weiss BD et. al.

Feb 25th, 2021 - 18F-2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) shows tumor activity in most neuroblastomas, but the role of 18F-FDG PET/CT in neuroblastoma remains to be defined. This study explored the prognostic significance of 18F-FDG PET...

Mixed Findings in Pediatric Neuroblastoma CAR-T Therapy Trial.
https://doi.org/10.1001/jama.2020.26233
JAMA Abbasi J

Jan 12th, 2021 - Mixed Findings in Pediatric Neuroblastoma CAR-T Therapy Trial.|2021|Abbasi J,|therapy,therapeutic use,

Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320557
BMC Pediatrics; Wang H, Wang X et. al.

Jun 30th, 2020 - Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. The expression profiles of MYCN associated genes were identified from Therap...

How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival i...
https://doi.org/10.1007/s00383-020-04696-y
Pediatric Surgery International; Parhar D, Joharifard S et. al.

Jun 13th, 2020 - Since their introduction to the International Neuroblastoma Risk Group (INRG) staging system in 2009, the role of Image-Defined Risk Factors (IDRFs) in predicting outcomes has been studied in heterogeneous populations with varying results. We cond...

Imaging Biomarkers of the Physis: Cartilage Volume on MRI vs. Tract Volume and Length o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410391
Journal of Magnetic Resonance Imaging : JMRI; Duong P, Mostoufi-Moab S et. al.

Feb 10th, 2020 - Current methods to predict height and growth failure are imprecise. MRI measures of physeal cartilage are promising biomarkers for growth. In the physis, to assess how 3D MRI volume measurements, and diffusion tensor imaging (DTI) measurements (tr...

see more →

Clinicaltrials.gov  107 results

Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed t...
https://doi.org/10.1007/s00247-021-05005-y 10.1016/S0140-6736(07)60983-0 10.1001/jama.2019.11642 10.1200/JCO.2008.16.6876 10.18632/oncotarget.7933 10.1200/JCO.2001.19.14.3397 10.2967/jnumed.108.060467 10.1016/j.ejrad.2015.09.027 10.1007/s13139-016-0451-8 10.2967/jnumed.110.083303 10.1097/RLU.0000000000001529
Pediatric Radiology; Sung AJ, Weiss BD et. al.

Feb 25th, 2021 - 18F-2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) shows tumor activity in most neuroblastomas, but the role of 18F-FDG PET/CT in neuroblastoma remains to be defined. This study explored the prognostic significance of 18F-FDG PET...

Mixed Findings in Pediatric Neuroblastoma CAR-T Therapy Trial.
https://doi.org/10.1001/jama.2020.26233
JAMA Abbasi J

Jan 12th, 2021 - Mixed Findings in Pediatric Neuroblastoma CAR-T Therapy Trial.|2021|Abbasi J,|therapy,therapeutic use,

Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320557
BMC Pediatrics; Wang H, Wang X et. al.

Jun 30th, 2020 - Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. The expression profiles of MYCN associated genes were identified from Therap...

How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival i...
https://doi.org/10.1007/s00383-020-04696-y
Pediatric Surgery International; Parhar D, Joharifard S et. al.

Jun 13th, 2020 - Since their introduction to the International Neuroblastoma Risk Group (INRG) staging system in 2009, the role of Image-Defined Risk Factors (IDRFs) in predicting outcomes has been studied in heterogeneous populations with varying results. We cond...

Imaging Biomarkers of the Physis: Cartilage Volume on MRI vs. Tract Volume and Length o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410391
Journal of Magnetic Resonance Imaging : JMRI; Duong P, Mostoufi-Moab S et. al.

Feb 10th, 2020 - Current methods to predict height and growth failure are imprecise. MRI measures of physeal cartilage are promising biomarkers for growth. In the physis, to assess how 3D MRI volume measurements, and diffusion tensor imaging (DTI) measurements (tr...

see more →

News  3 results

Tandem transplants provide EFS edge in pediatric neuroblastoma
https://www.mdedge.com/neurology/article/207309/cns/brain-cancer/tandem-transplants-provide-efs-edge-pediatric?channel=27970
Neil Osterweil

Aug 29th, 2019 - For young patients with high-risk neuroblastoma, an intensive consolidation regimen with tandem autologous stem cell transplants was associated with significantly better event-free survival, compared with single-transplant consolidation, results o.

cfDNA reveals targetable mutations in pediatric neuroblastoma, sarcoma
https://www.mdedge.com/hematology-oncology/article/166137/sarcoma-gist/cfdna-reveals-targetable-mutations-pediatric/page/0/1

May 20th, 2018 - For example, in one patient with stage 4 MYCN-amplified neuroblastoma, both tumor analysis and cfDNA revealed MYCN amplification, but cfDNA also show multiple new mutations, including a targetable NRAS mutation, secondary to clonal mutation. In 5.

ASCO 2009: Immunotherapy Prolongs Survival in High-risk Pediatric Neuroblastoma
https://www.medscape.com/viewarticle/703011

May 18th, 2009 - May 19, 2009 — An experimental immunotherapy product has been shown to improve overall survival and to reduce the risk for relapse in children with high-risk neuroblastoma. The results from a phase 3 clinical trial are due to be presented at the u...

see more →